Asieris Presents Phase II Clinical Study Results of APL-1202 in Combined with PD-1 Inhibitor Tislelizumab as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer at 2025 ASCO-GU
February 14, 2025 Asieris Presents Phase II Clinical Study Results of APL-1202 in Combined with PD-1 Inhibitor Tislelizumab as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer at 2025 ASCO-GU
January 24, 2025 Asieris Selected as the Top 10 Exhibitors with Communication Influence” in the Innovation Incubation Special Section of the 7th CIIE
January 16, 2025 Asieris Received NMPA IND Approval for a Novel USP1 Inhibitor for the Treatment of Advanced Solid Tumors
January 6, 2025 Asieris and CDC Sign Investigational Product Supply Agreement for APL-1202 in Free-Living Amoeba Infections Treatment under Expanded Access Investigational New Drug Program